Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Test dose-guided administration of cisplatin in an anephric patient: a case reportV Ribrag, J P Droz, J Morizet, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouseG G Chabot, D Branellec, A Sassi, et al.
Journal of the National Cancer Institute|April 20, 2000
Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategyD Vandier, V Calvez, L Massade, et al.
Biochemical and Biophysical Research Communications|December 30, 1986
Tumor cell biotransformation products of prostaglandin A1 with growth inhibitory activityE Gouin, B Vulliez-Le Normand, A Gouyette, et al.
Drug Development and Industrial Pharmacy|August 6, 1999
Development of a "continuous-flow adhesion cell" for the assessment of hydrogel adhesionA M Le Ray, P Iooss, A Gouyette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patientsD Abigerges, G G Chabot, J P Armand, et al.
Anticancer Research|November 1, 1988
Antitumour activity of a new water-soluble nitrosoureido sugar: CY233 (NSC 609224)C Gosse, G Atassi, Y Letourneux, et al.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials|October 2, 2007
Biphasic calcium phosphate: a comparative study of interconnected porosity in two ceramicsA Lecomte, H Gautier, J M Bouler, et al.
Journal of Photochemistry and Photobiology. B, Biology|July 1, 1997
In vitro and in vivo spectrofluorometry of a water-soluble meta-(tetrahydroxyphenyl)chlorin (m-THPC) derivativeL Morlet, V Vonarx, M T Foultier, et al.
Biomaterials|November 9, 2002
Vancomycin encapsulation in biodegradable poly(epsilon-caprolactone) microparticles for bone implantation. Influence of the formulation process on size, drug loading, in vitro release and cytocompatibilityA-M Le Ray, S Chiffoleau, P Iooss, et al.
Pageof 10